Does the Impact of <scp>COVID</scp>‐19 on Patients With Systemic Sclerosis Change Over Time?
Elisabeth Deibel(University of Zurich), Fabian A. Mendoza(Thomas Jefferson University), Fabiola Atzeni(University of Messina), Rosario Foti(Université Paris Cité), Jörg Henes(University of Tübingen), Laura Belloli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Alexandra Balbir‐Gurman(Technion – Israel Institute of Technology), Gabriela Riemekasten(Universitäres Kinderwunschzentrum Lübeck), Vanessa Smith(Ghent University Hospital), Maurizio Cutolo(Ospedale Policlinico San Martino), Gianluca Moroncini(Marche Polytechnic University), Gabriella Szűcs(University of Debrecen), Sophie I E Liem(Leiden University Medical Center), Corrado Campochiaro(Vita-Salute San Raffaele University), Marcin Milchert(Pomeranian Medical University), Paolo Airó(University of Lisbon), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), Alessandro Giollo(University of Verona), Jeska de Vries‐Bouwstra(Leiden University Medical Center), Simona Rednic(Charité - Universitätsmedizin Berlin), Madelon C Vonk(Radboud University Nijmegen), Stylianos Panopoulos(National and Kapodistrian University of Athens), Juan José Alegre Sancho(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Hadi Poormoghim(Firoozgar General Hospital), Şule Yavuz(KU Leuven), Vera Bernardino(Unidade Local de Saúde de São José), L. Garzanova(Association of Rheumatologists of Russia), Ignasi Rodríguez‐Pintó(Hospital Clínic de Barcelona), Francesco Del Galdo(University of Leeds), Patrícia Carreira, Giacomo De Luca(Vita-Salute San Raffaele University), Radim Bečvář(Charles University), Julia Spierings(The Royal Free Hospital), Carina Mihai(Carol Davila University of Medicine and Pharmacy), Nicoletta Del Papa(University of Milan), Maria De Santis(Medical University of Vienna), Masataka Kuwana(Nippon Medical School), Maria Grazia Lazzaroni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Emmanuel Chatelus(Laboratoire National de Référence), Daniel Brito de Araújo(Universidade Federal de Pelotas), Murat İnanç(Istanbul University), A. Mékinian(Sorbonne Université), Alessandra Vacca(University of Cagliari), Elisabetta Zanatta(University of Padua), Thierry Martin(Western Infirmary), Christopher P. Denton(The Royal Free Hospital), Sergey Moiseev(Sechenov University), Jose‐Luis Tandaipan(Hospital de Sant Pau), Edoardo Rosato(Sapienza University of Rome)
Cited by 2
Related Papers
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456